Description
Product Overview: KPV (Lysine-Proline-Valine)
KPV is a potent tripeptide (Lysine-Proline-Valine) representing the active C-terminal fragment of Alpha-Melanocyte-Stimulating Hormone ($\alpha$-MSH). Engineered to preserve the powerful anti-inflammatory and antimicrobial properties of native $\alpha$-MSH without inducing pigment production, KPV enters cell nuclei to directly suppress NF-$\kappa$B transcription pathways, making it a valuable subject for research into gastrointestinal health, mucosal repair, and chronic inflammatory conditions.
Primary Research Applications & Reasons for Study
- Intestinal & Mucosal Healing: Evaluating epithelial cell migration, tight-junction maintenance, and intestinal mucosa restoration in models of inflammatory bowel disease (IBD) and colitis.
- Nuclear Inactivation of NF-κB: Studying direct intracellular trans-location mechanisms that block pro-inflammatory gene expression and cytokine release ($\text{IL-6}$, $\text{IL-1}\beta$, $\text{TNF-}\alpha$).
- Antimicrobial & Anti-Fungal Activity: Investigating broad-spectrum structural disruption of pathogenic microorganisms, including Candida albicans and Staphylococcus aureus assays.
- Dermal & Mast Cell Regulation: Assessing the downregulation of histamine release, mast cell degranulation, and inflammatory cascades in psoriasis and dermatitis cell models.
Expected Research Results & Timeline Metrics
-
Phase 1 / Days 1–3
Intracellular Transport & NF-κB Suppression: Rapid intracellular cellular uptake leading to immediate nuclear entry and measurable reduction in acute inflammatory signaling. -
Phase 2 / Weeks 1–3
Epithelial Barrier & Antimicrobial Clearance: Statistically significant reduction in intestinal permeability, restoration of tight junctions (ZO-1, occludin), and suppression of pathogenic microbial colonies. -
Phase 3 / Weeks 4–8
Mucosal Remodeling & Immune Normalization: Sustained healing of mucosal tissue, resolution of chronic gastrointestinal inflammation, and stabilization of epithelial defense barriers.
Key Research Benefits
- Non-Pigmenting Profile: Delivers the anti-inflammatory potency of $\alpha$-MSH without binding to MC1R to induce melanogenesis (skin darkening).
- Ultra-Compact Tripeptide: Small molecular size enables high bioavailability, rapid tissue uptake, and efficient intracellular nuclear translocation.
- Dual-Action Therapeutic Model: Simultaneously exhibits anti-inflammatory signaling reduction and direct endogenous antimicrobial properties.
- Targeted Gut Health Tool: Highly stable in gastrointestinal research models for targeted evaluation of inflammatory bowel pathologies.
THIS PRODUCT IS INTENDED SOLELY FOR IN VITRO LABORATORY RESEARCH AND EXPERIMENTAL PURPOSES. It is strictly prohibited for human consumption, clinical trials, therapeutic administration, cosmetic use, or veterinary application. This product is not an FDA-approved drug, medical food, or dietary supplement. It is not intended to diagnose, treat, cure, or prevent any disease, illness, or medical condition. Any handling, reconstitution, or experimentation involving this chemical compound must be conducted strictly by qualified, trained laboratory professionals utilizing appropriate containment and personal protective equipment in accordance with scientific biosafety standards. Buyers and users assume full liability for compliance with local, state, and federal laws regarding the handling and possession of research compounds.